peptide drug conjugate Conjugation with peptides helps to overcome their inherent drawbacks - Peptide drug conjugateFDA-approved drug Peptide Drug Conjugates: Revolutionizing Targeted Therapies

Research advances inpeptide drugconjugates The landscape of therapeutic development is constantly evolving, with a growing emphasis on precision medicine and minimizing off-target effects. In this pursuit, peptide drug conjugates (PDCs) have emerged as a highly promising area, representing a significant advancement in the field of targeted drug delivery作者：L Gong·2023·被引用次数：90—Peptide‒drug conjugates (PDCs) aredrug delivery systems consisting of a drug covalently coupled to a multifunctional peptidevia a cleavable linker.. These innovative therapeutic agents are designed to deliver potent drugs directly to specific cells, particularly in the context of cancer treatment. Peptide drug conjugates are essentially drugs covalently linked to peptides, forming a sophisticated system that leverages the inherent targeting capabilities of peptides with the cytotoxic power of therapeutic moleculesPeptide-drug conjugates.

Drawing inspiration from the success of antibody-drug conjugates (ADCs), peptide drug conjugates (PDCs) are increasingly recognized as the next generation of targeted therapeutics. While ADCs utilize large antibodies for targeting, PDCs employ smaller peptide molecules. This distinction offers several core benefits, including enhanced cell permeability and improved drug selectivity.作者：D Wang·2025·被引用次数：29—Similar to ADCs, peptide-drug conjugates (PDCs) are defined asdrugs covalently linked to peptideswith certain functions via specialized ... Furthermore, conjugation with peptides helps to overcome their inherent drawbacks such as poor solubility, short half-life, drug resistance, and systemic toxicity often associated with traditional drug delivery methods.2021年7月9日—PDC (Peptide Drug Conjugate) isa new type of coupled drug, whose structure contains three main elements - a cytotoxic agent, a homing peptide and a linker ...

The fundamental structure of a peptide drug conjugate typically comprises three key elements: a cytotoxic agent (also referred to as a payload), a peptide component that acts as the targeting moiety, and a linker that covalently connects the peptide to the drug2025年2月19日—Peptide drug conjugatesare a class of biopharmaceuticals that combine a therapeutic peptide with a cytotoxic or biologically active drug. The .... The peptide sequence is carefully selected for its ability to bind to specific receptors or antigens that are overexpressed on diseased cells. Once bound, the peptide drug conjugate can be internalized by the cell, releasing the drug payload to exert its therapeutic effect. This targeted approach not only enhances efficacy but also significantly reduces the exposure of healthy tissues to the toxic drug, thereby minimizing adverse side effects.

The development of peptide drug conjugates is a complex process that involves determining the finest conjugation reaction to ensure a stable and effective link between the peptide and the drug.多肽偶联药物(PDCs) 是继抗体偶联药物(ADCs) 之后的新一代靶向治疗药物，在肿瘤治疗等领域具有广阔的前景。PDCs 结合了肽的选择性和化疗药物的杀伤力，其核心优势是增强细胞 ... Researchers are actively exploring various conjugation strategies and linker technologies to optimize the release kinetics of the payload and improve the overall therapeutic profile of these agents.Review Peptide–drug conjugate-based novel molecular ... The drug delivery systems often consist of a drug covalently coupled to a multifunctional peptide via a cleavable linker, allowing for controlled release within the target cell.

The potential applications of peptide drug conjugates extend beyond cancer therapy.作者：E Heh·2023·被引用次数：84—Peptide-drug conjugates (PDCs), a subset of drug conjugates,are composed of carrier peptides ranging from 5 to 30 amino acid residues, toxic payloads, and ... Their ability to precisely deliver therapeutic agents to specific cellular targets makes them valuable for treating a wide range of diseases. The synergistic peptides and small molecules can be used to overcome complex disease states and resistance mechanisms. As such, peptide drug conjugates have emerged as promising precision medicine tools due to their enhanced efficacy and safety profiles.

In essence, peptide drug conjugates (PDCs) are not just a new type of coupled drug; they represent a new paradigm for targeted cancer therapy and a new frontier in targeted therapeutics. They are innovative therapeutic agents designed to deliver drugs directly to specific cells, offering a strong and powerful tumor-killing agents with targeted therapy and minimal side effects for cancer patients.Combining cell-targeting and efficient cell-killing properties,peptide–drug conjugates (PDCs) have demonstrated superior efficacy compared with peptides and ... The ongoing research and development in this field, including the establishment of databases like PDCdb, highlight the significant progress and future potential of peptide drug conjugates in revolutionizing patient care.